SomaLogic, UPMC partner on protein study

BOULDER — SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company that went public this month in a merger with a special purpose acquisition company, and the University of Pittsburgh Medical Center are joining forces to study how proteins may be used in clinical care. 

SomaLogic develops platforms to read thousands of proteins in a patient’s blood or urine sample that may signal illnesses or future health conditions and suggest potential treatments via machine learning.

“As part of the agreement, UPMC and SomaLogic will establish a collaboration to promote the use of proteomic data in building healthier communities, improving patient care and…